Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial


Por: Català-Moll, F, Blázquez-Bondia, C, Farré-Badia, J, Torres, F, Manzardo, C, Bonfill, E, Curran, A, Domingo, P, Podzamczer, D, Force, L, Falcó, V, Parera, M, Casadellà, M, Miró, JM, Noguera-Julian, M and Paredes, R

Publicada: 4 mar 2026
Resumen:
Late presentation of HIV-1 infection is linked to gut dysbiosis, impaired immune reconstitution, excess inflammation, immune activation, and increased morbidity and mortality. It is unclear if antiretroviral therapy initiation can reverse HIV-associated gut dysbiosis at all, or if specific antiretroviral regimens are more effective in restoring the gut microbiota than others. This has important implications for the long-term health of individuals with HIV. In this multicenter, open-label, randomized clinical trial (NCT02337322), 88 antiretroviral-na & iuml;ve individuals with advanced HIV-1 infection (median CD4+ T cells of 34 cells/mm3) were randomized (1:1) to initiate lamivudine/abacavir plus either dolutegravir or ritonavir-boosted darunavir, and were followed for 2 years. Both groups had similar HIV-1 suppression rates and recovery of CD4+ T cells. However, treatment with dolutegravir led to increased gut microbial richness and diversity and enrichment of specific microbial taxa and metabolic pathways. These changes were associated with reduced inflammation and lower immune activation, outcomes that did not occur with darunavir/ritonavir. After two years, participants on dolutegravir-based therapy had gut microbiota profiles more closely resembling those of people without HIV, compared to individuals taking darunavir/ritonavir. In summary, dolutegravir-based therapy restores the gut microbiota more effectively than darunavir/ritonavir in patients who present late with HIV.

Filiaciones:
:
 IrsiCaixa, Badalona, Barcelona, Spain

 Carlos III Hlth Inst, Infect Dis Networking Biomed Res Ctr, Ctr Invest Biomed Red Enfermedades Infecciosas, Madrid, Spain

Blázquez-Bondia, C:
 IrsiCaixa, Badalona, Barcelona, Spain

 Univ Autonoma Barcelona, Bellaterra, Catalonia, Spain

Farré-Badia, J:
 IrsiCaixa, Badalona, Barcelona, Spain

Torres, F:
 Univ Barcelona, Hosp Clin IDIBAPS, Barcelona, Catalonia, Spain

 Univ Autonoma Barcelona, Med Sch, Biostat Unit, Bellaterra, Catalonia, Spain

Manzardo, C:
 Univ Barcelona, Hosp Clin IDIBAPS, Barcelona, Catalonia, Spain

Bonfill, E:
 Univ Barcelona, Hosp Clin IDIBAPS, Barcelona, Catalonia, Spain

Curran, A:
 Univ Autonoma Barcelona, Bellaterra, Catalonia, Spain

 Hosp Univ Vall dHebron VHIR, Barcelona, Catalonia, Spain

Domingo, P:
 Hosp Univ Santa Creu & St Pau, Barcelona, Catalonia, Spain

Podzamczer, D:
 Hosp Univ Bellvitge, Lhospitalet De Llobregat, Catalonia, Spain

Force, L:
 Hosp Univ Mataro, Barcelona, Catalonia, Spain

Falcó, V:
 Univ Autonoma Barcelona, Bellaterra, Catalonia, Spain

 Hosp Univ Vall dHebron VHIR, Barcelona, Catalonia, Spain

:
 IrsiCaixa, Badalona, Barcelona, Spain

:
 IrsiCaixa, Badalona, Barcelona, Spain

 Univ Autonoma Barcelona, Bellaterra, Catalonia, Spain

Miró, JM:
 Carlos III Hlth Inst, Infect Dis Networking Biomed Res Ctr, Ctr Invest Biomed Red Enfermedades Infecciosas, Madrid, Spain

 Univ Barcelona, Hosp Clin IDIBAPS, Barcelona, Catalonia, Spain

 Reial Acad Med Catalunya, Barcelona, Spain

Noguera-Julian, M:
 IrsiCaixa, Badalona, Barcelona, Spain

:
 IrsiCaixa, Badalona, Barcelona, Spain

 Carlos III Hlth Inst, Infect Dis Networking Biomed Res Ctr, Ctr Invest Biomed Red Enfermedades Infecciosas, Madrid, Spain

 Univ Politecn Catalunya BarcelonaTech, Terrassa, Catalonia, Spain

 Hosp Badalona Germans Trias & Pujol, Dept Infect Dis, Badalona, Catalonia, Spain

 Case Western Reserve Univ, Sch Med, Ctr Global Hlth & Dis, Dept Pathol, Cleveland, OH 44106 USA

 Hosp Badalona Germans Trias & Pujol, Fundacio Lluita Infecc, Badalona, Spain
ISSN: 20411723





Nature Communications
Editorial
Nature Publishing Group, HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY, Reino Unido
Tipo de documento: Article
Volumen: 17 Número: 1
Páginas:
WOS Id: 001714869100001
ID de PubMed: 41781390
imagen Green Submitted, gold

MÉTRICAS